Learn more about Arlene Coulson’s (Lead Clinical Pharmacist) experience with OCREVUS SC homecare at NHS Tayside, as part of the At The Limits 2025 Roche symposium. In this video, Arlene shares her experience with the homecare pathway, set up process, and the impact on patients and NHS Tayside so far.

The video is divided into different chapters, you can access these by hoovering your cursor over the video's progress bar and clicking your desired chapter. Also, you can find written highlights of Arlene’s experience below the video.

If you would like to learn more about a particular highlight, please see the timestamp relating to the corresponding section in the video. Please note that these highlights reflect Arlene’s experiences with OCREVUS SC homecare at NHS Tayside, but experiences from other Trusts may vary.

OCREVUS SC homecare service (00:33 - 03:18)

• The OCREVUS SC homecare service includes:
  • Prescription management
  • Dispensing
  • Medication home delivery
  • Nurse administration
  • Phlebotomy services
  • Medical waste removal
• Delivery of the medication to patient is typically arranged within five days of receipt of valid documentation, with nurse administration occurring within the subsequent five days
• Homecare nurses provide a detailed patient summary on the day of administration, which is sent back to the health board and uploaded to the patient’s electronic record
   

Current status in NHS Tayside (03:18 - 04:24)

• NHS Tayside started with the OCREVUS SC homecare service in June 2025
• The majority of patients (68%) agreed to take up the homecare service upfront with ~100 patients receiving OCREVUS SC at home by December
• Other patients wanted to ‘wait and see’ (e.g. on the experience of other patients) and a few were deemed not suitable for administration at home by their consultants
   

Set up process (04:24 - 07:35)

• Relieving hospital infusion capacity constraints was a key motivation to set up the homecare service
• Additional motivations included patient choice and ensuring treatment location was not a limiting factor in patient access
• The transition to the homecare service was led by the Neuropharmacist (Arlene Coulson), who also took responsibility for signing the initial injection prescriptions
• Eligible patients were transitioned “in bulk”, with each patient given the choice to opt out and receiving follow-up calls to address any concerns
• The homecare company (Healthnet) supported the transition by pre-populating registration forms and prescriptions, easing the administrative workload on the MS Team
   

Impact on patients (07:35 - 12:22)

• 36 patients provided feedback on their OCREVUS SC homecare service experience
• Experience with OCREVUS SC homecare was highly positive with a ~94% satisfaction rate (75% with OCREVUS IV hospital administration)
• This increase in satisfaction was largely attributed to reduced travel burden and stress
• Patients praised the homecare nurses with 97% of patients describing the homecare nurses as professional, supportive, and reassuring
• Patients reported meaningful improvements in quality of life (47% reported better quality of life) and 84% would recommend homecare service to others
   

Impact on NHS Tayside (12:22 - 16:16)

• The MS Team provided 100% "Good" or "Excellent" ratings for the homecare service, citing high trust in nurse competency and excellent communication
• Initial challenges around scheduling and concerns regarding the homecare providers have been resolved out through fine tuning the process
• The homecare service freed up 100 bed days per 6 months, reduced the burden on the MS Team, and eliminated wait times for new patients starting on OCREVUS